ClinicalTrials.gg
RecruitingNCT03729232J-ABUpdated Nov 12, 2026

Japanese Catheter Ablation Registry

An observational study in Catheter Ablation and Cardiac Arrhythmias, sponsored by National Cerebral and Cardiovascular Center, Japan. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Cerebral and Cardiovascular Center, Japan · Observational

How we know

From the registry’s dates

  • Started Jul 2017; still recruiting 9 years 4 months later.
Updated Nov 12, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
400,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Arrhythmias, Cardiac with a site in Japan — 6 open to participants now, 6 under way, none of them phase 3. Arrhythmias, Cardiac · Japan.

Planned enrollment
Largest of 15
400,000 · median 1,604
Started
2017
with 2 others
Observational
15 of 23
4 open now
Registered
18th of 23
by date
Lead sponsor
2 of 23
National Cerebral and Cardiovascular Center, Japan

Among the 23 studies in Arrhythmias, Cardiac with a site in Japan, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2017, is one of 15 observational ones, and was the 18th registered.

Arrhythmias, Cardiac

1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

6 of the 23 studies in Arrhythmias, Cardiac with a site in Japan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Arrhythmias, Cardiac with a site in Japan, or all of them as a file.
02

Study summary

Japanese Cather Ablation (J-AB) Registry is a voluntary nationwide registry, performed by Japanese Heart Rhythm Society, collaborated with the National Cerebral and Cardiovascular Center. The objectives of this registry are to observe and describe developments in the catheter ablation treatment of arrhythmia in Japan and to provide reliable information on the type of activity performed and the facilities available in Japanese arrhythmia units.

Read the detailed description

Japanese Cather Ablation (J-AB) Registry is a nationwide, multicenter, observational registry, performed by Japanese Heart Rhythm Society, collaborated with National Cerebral and Cardiovascular Center.

This study is a voluntary nationwide registry and data are collected prospectively using a Research Electronic Data Capture (REDCap) system. Detailed data collection including antiarrhythmic medication is also performed at every September. The acute success rate at discharge and the complications associated with ablation procedure will be collected in all cases. Major bleeding events are defined according to Bleeding Academic Research Consortium criteria. Based on the provided information, the annual incidence and predictive factors for outcome will be investigated by the event assessment committee.

03

Conditions studied

  • Catheter Ablation
  • Cardiac Arrhythmias

Keywords

  • Catheter Ablation
  • Cardiac Arrhythmias
  • Registry
  • Complication
  • REDCap
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Inpatients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients treated with catheter ablation in Japan

Exclusion criteria

Exclusion Criteria:

  • Patients who refused to consent
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
400,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients with recurrence of targeted arrhythmia

    Time frame: Through discharge from hospital, approximately up to 1 weeks

Secondary outcomes

  1. Number of deaths

    All-cause death, cardiovascular death, and procedure-related death

    Time frame: Through discharge from hospital, approximately up to 1 weeks

  2. Number of patients with treatment-related complications

    Bleeding events, embolic events, other all complications. Major bleeding events are defined according to Bleeding Academic Research Consortium criteria.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Matsuda Y, Masuda M, Kanaoka K, Mano T, Inoue K, Yamashita S, Iwasaki YK, Nakamura K, Nagashima K, Miyamoto K, Satomi K, Takatsuki S, Kusano K, Yamane T, Shimizu W. Real-World Outcomes of Repeat Ablation Strategies for Atrial Fibrillation: Insights From the Japanese Catheter Ablation Registry. J Arrhythm. 2025 Sep 22;41(5):e70200. doi: 10.1002/joa3.70200. eCollection 2025 Oct. PubMed 40995616 ↗
  • Goto K, Miyazaki S, Tonegawa-Kuji R, Kanaoka K, Yamashita S, Sasano T, Iwanaga Y, Nakai M, Inoue K, Iwasaki YK, Nagashima K, Nakamura K, Masuda M, Miyamaoto K, Satomi K, Takatsuki S, Kusano K, Yamane T, Shimizu W. Efficacy and Safety of Second Sessions of Catheter Ablation for Idiopathic Premature Ventricular Contractions: From the Nationwide Japan Catheter Ablation Registry. J Arrhythm. 2025 Aug 25;41(4):e70181. doi: 10.1002/joa3.70181. eCollection 2025 Aug. PubMed 40861252 ↗
  • Oikawa J, Fukaya H, Kanaoka K, Niwano S, Miyamoto K, Iwanaga Y, Iwasaki YK, Nagashima K, Masuda M, Yamashita S, Nakamura K, Satomi K, Takatsuki S, Inoue K, Kusano K, Yamane T, Tada H, Shimizu W. Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation: A comparison of first-line vs second-line therapy. Heart Rhythm. 2026 Jul;23(7):1496-1503. doi: 10.1016/j.hrthm.2025.07.030. Epub 2025 Jul 24. PubMed 40714332 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Mar 2030, 152 months after the start.

Of 190 non-industry observational studies under Arrhythmias, Cardiac, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 140. This study's planned 152 months is above that.

Counting every sponsor, half of 259 studies reached it within 38 months; a quarter within 16 and three quarters within 97.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2030 → Mar 2031, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2018
First posted
Nov 2, 2018
StartActual
Jul 1, 2017
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2031was Mar 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Mar 31, 2030→Mar 31, 2031
Nov 12, 2026
Publications
3 publications citing this study linked from PubMed, e.g. PubMed 40995616 ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Publications 3 publications citing this study linked from PubMed, e.g. PubMed 40995616 ↗
    Study completion Mar 31, 2030→Mar 31, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03729232
Lead sponsor
National Cerebral and Cardiovascular Center, Japan
Responsible party
Kengo Kusano (Director of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, National Cerebral and Cardiovascular Center, Japan) — Principal investigator
First posted
Nov 2, 2018
Start date
Jul 1, 2017
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Kengo Kusano, MD, PhD
Contact
kusanokengo@ncvc.go.jp
+81-6-6170-1070
Misa Takegami, PhD, MPH
Contact
takegami@ncvc.go.jp
+81-6-6170-1070
Teiichi Yamane, MD, PhD
principal investigator · Jikei University School of Medicine
Kengo Kusano, MD, PhD
principal investigator · National Cerebral and Cardiovascular Center, Japan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion